Alvimopan

From WikiMD's Wellness Encyclopedia

(Redirected from Entereg)

What is Alvimopan?[edit | edit source]

Alvimopan
Alvimopan molecule ball



What are the uses of this medicine?[edit | edit source]

  • Alvimopan (Entereg) is used in people to avoid postoperative ileus following partial large or small bowel resection with primary anastomosis.
  • Alvimopan accelerates the gastrointestinal recovery period as defined by time to first bowel movement or flatus.


How does this medicine work?[edit | edit source]

  • Alvimopan is a selective antagonist of the cloned human μ-opioid receptor.
  • Postoperative ileus is the impairment of gastrointestinal motility after intra-abdominal surgery or other, non-abdominal surgeries. Postoperative ileus affects all segments of the gastrointestinal tract and may last from 5 to 6 days, or even longer.
  • This may potentially delay gastrointestinal recovery and hospital discharge until its resolution.
  • It is characterized by abdominal distention and bloating, nausea, vomiting, pain, accumulation of gas and fluids in the bowel, and delayed passage of flatus and defecation.
  • Morphine and other μ-opioid receptor agonists are universally used for the treatment of acute postsurgical pain; however, they are known to have an inhibitory effect on gastrointestinal motility and may prolong the duration of postoperative ileus.
  • Following oral administration, alvimopan antagonizes the peripheral effects of opioids on gastrointestinal motility and secretion by competitively binding to gastrointestinal tract μ-opioid receptors.
  • Alvimopan achieves this selective gastrointestinal opioid antagonism without reversing the central analgesic effects of μ-opioid agonists.


Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients who:

  • have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking Entereg.


What drug interactions can this medicine cause?[edit | edit source]

  • Dosage adjustment for intravenously administered morphine is not necessary when it is coadministered with Entereg.
  • No dosage adjustments are necessary in patients taking acid blockers or antibiotics with Entereg.


Is this medicine FDA approved?[edit | edit source]


How should this medicine be used?[edit | edit source]

Recommended dosage:

  • The recommended adult dosage of Entereg is 12 mg administered 30 minutes to 5 hours prior to surgery followed by 12 mg twice daily beginning the day after surgery until discharge for a maximum of 7 days.
  • Patients should not receive more than 15 doses of Entereg.

Administration:

  • Entereg can be taken with or without food.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Capsules: 12 mg

This medicine is available in fallowing brand namesː

  • Entereg


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:


What special precautions should I follow?[edit | edit source]

  • A higher number of myocardial infarctions was reported in patients treated with Entereg 0.5 mg twice daily compared with placebo in a 12-month study in patients treated with opioids for chronic non-cancer pain, although a causal relationship with long-term use has not been established.
  • Patients recently exposed to opioids may be more sensitive to the effects of Entereg and experience gastrointestinal adverse reactions (e.g., abdominal pain, nausea and vomiting, and diarrhea).
  • Patients with severe hepatic impairment may be at higher risk of serious adverse reactions (including dose-related serious adverse reactions). Therefore, the use of Entereg is not recommended in this population.
  • No studies have been conducted in patients with end-stage renal disease. Entereg is not recommended for use in these patients.
  • No studies have been conducted in patients with complete gastrointestinal obstruction or in patients who have surgery for correction of complete bowel obstruction; use is not recommended.
  • Entereg has not been studied in patients having pancreatic or gastric anastomosis. Therefore, Entereg is not recommended for use in these patients.


What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.


Can this medicine be used in pregnancy?[edit | edit source]

  • Available data regarding use of Entereg in pregnant women are limited, and are insufficient to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.


Can this medicine be used in children?[edit | edit source]

  • Safety and effectiveness in pediatric patients have not been established.


What are the active and inactive ingredients in this medicine?[edit | edit source]

Active ingredient:

  • alvimopan

Inactive ingredients:

  • POLYETHYLENE GLYCOL, UNSPECIFIED
  • GELATIN, UNSPECIFIED


Who manufactures and distributes this medicine?[edit | edit source]

Manufactured for:

Manufactured by:

  • Pharmaceutical Manufacturing Research Services, Inc., Horsham, PA, USA


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F).


Alvimopan Resources


Contributors: Deepika vegiraju